Isoflavone Glycitein Diminished Plasma Cholesterol in Female Golden Syrian Hamsters by Lee, Sun-Ok et al.
Food Science and Human Nutrition Publications Food Science and Human Nutrition
11-27-2007
Isoflavone Glycitein Diminished Plasma
Cholesterol in Female Golden Syrian Hamsters
Sun-Ok Lee
Iowa State University
Mathieu Renouf
Iowa State University
Zhong Ye
Iowa State University
Patricia A. Murphy
Iowa State University, pmurphy@iastate.edu
Suzanne Hendrich
Iowa State University, shendric@iastate.edu
Follow this and additional works at: http://lib.dr.iastate.edu/fshn_ag_pubs
Part of the Agricultural Science Commons, Animal Sciences Commons, Food Science
Commons, and the Human and Clinical Nutrition Commons
The complete bibliographic information for this item can be found at http://lib.dr.iastate.edu/
fshn_ag_pubs/82. For information on how to cite this item, please visit http://lib.dr.iastate.edu/
howtocite.html.
This Article is brought to you for free and open access by the Food Science and Human Nutrition at Digital Repository @ Iowa State University. It has
been accepted for inclusion in Food Science and Human Nutrition Publications by an authorized administrator of Digital Repository @ Iowa State
University. For more information, please contact digirep@iastate.edu.
Isoflavone Glycitein Diminished Plasma Cholesterol
in Female Golden Syrian Hamsters
SUN-OK LEE,† MATHIEU RENOUF,‡ ZHONG YE,§ PATRICIA A. MURPHY,| AND
SUZANNE HENDRICH*
Food Science & Human Nutrition, Iowa State University, Ames, Iowa 50011
The soybean isoflavones, daidzein, genistein, and glycitein, were hypothesized to act as cholesterol-
lowering components, separate from soy protein. Pure synthetic daidzein, genistein, or glycitein (0.9
mmol/kg diet) or a casein-based control diet was fed to groups of 10 female Golden Syrian hamsters
for 4 weeks. Hamsters fed glycitein had significantly lower plasma total (by 15%) and non-HDL (by
24%) cholesterol compared with those fed casein (P < 0.05). Daidzein and genistein’s effects on
these lipids did not differ from the effects of either casein or glycitein. Plasma HDL cholesterol and
triglyceride concentrations were not significantly affected by dietary treatments. The percentage of
urinary recovery of the ingested dose of each isoflavone was glycitein > daidzein > genistein (33.2%,
4.6%, 2.2%, respectively), with the apparent absorption of glycitein significantly greater than that of
the other isoflavones. These data suggest that glycitein’s greater cholesterol-lowering effect was
due to its greater bioavailability, as reflected in its urinary recovery compared with that of the other
isoflavones.
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INTRODUCTION
Soy isoflavones are the major phytoestrogens in soybeans and
soy foods. There is a great interest in soy isoflavones, daidzein,
genistein, and glycitein, regarding their possible effects on
plasma lipid levels. The role of soy isoflavones in lowering
plasma concentrations of lipoproteins and cholesterol has been
studied in animals (1–9) and humans (10–16).
Animal studies showed that isolated soy proteins containing
isoflavones or alcohol extracts of soy protein rich in isoflavones
were hypocholesterolemic with respect to plasma total and non-
HDL cholesterol concentrations compared with controls not fed
soy. Soy protein isolate (ISP) containing isoflavones (1.0 mmol/
kg diet) significantly lowered plasma total and LDL + VLDL
cholesterol concentrations in ovariectomized monkeys compared
with isoflavone-depleted ISP (0.005 mmol/kg diet) (7). Balmir
et al. (1) reported a significant reduction in plasma LDL
cholesterol in male hamsters fed diets containing intact ISP,
ISP with 0.6 mmol of total isoflavones/kg diet, or casein with
0.3 mmol of total isoflavones/kg diet compared with those fed
casein. Several human studies also reported that intake of soy
containing a large amount of isoflavones improved plasma lipid
profiles. Crouse et al. (12) found that consumption of 25 g of
isolated soy protein with 62 mg of isoflavones (∼0.5 mmol/kg
diet) significantly reduced the plasma total and LDL cholesterol
concentrations compared with consumption of casein. The
plasma LDL cholesterol concentration was significantly lessened
in premenopausal women consuming 53 g of isolated soy protein
with 129 mg of isoflavones (∼1.0 mmol/kg diet) compared with
women consuming isolated soy protein that contained 10 mg
of isoflavones (∼0.08 mmol/kg diet) (13).
Recent studies investigated the cholesterol-lowering effects
of pure synthetic isoflavones or isoflavones isolated from
soybean fractions (8, 17–19). Ovariectomized rats gavaged with
the isolated pure isoflavone glucosides daidzin (25 or 50 mg/
(kg body weight/day)) or glycitin (50 mg/(kg body weight/day))
showed significantly lesser plasma total cholesterol and tri-
glyceride concentrations compared with casein-fed rats (17).
Plasma triglyceride was significantly lessened in Sprague–
Dawley rats fed a mixture of synthetic daidzein and genistein
(1.4 mmol/kg diet or ∼23.6 mg/(kg body weight/day)) compared
with those fed casein (18). Hamsters fed pure synthetic daidzein
(1.3 mmol/kg diet or ∼16 mg/(kg body weight/day)) had
significantly lesser plasma total and non-HDL cholesterol
compared with those fed casein (8).
Isoflavone contents in urine or plasma may be considered as
a biological marker of soy consumption. We hypothesized that
soy isoflavones improve plasma cholesterol status and that
glycitein may have greater cholesterol-lowering efficacy because
glycitein is more absorbable compared with the other two
purified isoflavones in hamsters, based on preliminary studies
in our laboratory. To test these hypotheses, we fed pure synthetic
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daidzein, genistein, or glycitein to hamsters and then measured
plasma lipid concentrations and determined the association
between urinary recovery of each isoflavone and plasma lipid
concentrations. Hamsters were selected as an animal model
because hamsters and humans are similar in several aspects of
cholesterol metabolism. Hamsters fed a diet enriched with
saturated fat have greatly increased plasma total and LDL
cholesterol (20).
MATERIALS AND METHODS
Chemicals and Diets. The method of Chang et al. (21) was modified
to synthesize daidzein (22). Boron trifluoride diethyl etherate (0.5 mL)
was added to the mixture of 2,4,4′-trihydroxydeoxy benzoin (THB, 25
mg) and N,N-dimethylformamide (1 mL). The reaction mixture was
heated in a microwave for 21 s, and then methanesulfonyl chloride (1
mL) was added and heated again for 67 s at low energy. Distilled water
was added to the reaction mixture to obtain a yellowish precipitate.
The precipitate was centrifuged, washed with distilled water, and
recrystallized from methanol to give daidzein. Genistein was synthesized
by the method of Chang et al. (21). Glycitein was synthesized according
to Lang’at-Thoruwa et al. (23). The purity of isoflavones, determined
by HPLC chromatogram peak area and Beckman Gold HPLC system
peak purity software, was >97%. All chemicals for isoflavone synthesis
were purchased from Sigma-Aldrich (St. Louis, MO).
All dietary ingredients except rice flour were obtained from Harlan
Teklad (Madison, WI). Rice flour was purchased from Bioserv
(Frenchtown, NJ). Four treatments were fed: casein as control, and
casein-based diets supplemented with daidzein, genistein, or glycitein.
The content of each isoflavone was ∼30% less than the total molar
isoflavone content equivalent to feeding 25% isolated soy protein by
weight, 0.9 mmol/kg diet. The dose of isoflavones was ∼13 mg/(kg
body weight/day). The experimental diets contained ∼37% of energy
as fat, 25% casein, and 0.1% cholesterol (8). Rice flour was used as a
carbohydrate source to prevent “wet tail” disease, a chronic diarrhea
that may kill hamsters (1).
Animals. The use of animals and the experimental protocol were
approved by the Iowa State University Animal Care Center Committee.
Forty female Golden Syrian hamsters, 11–12 weeks old, were purchased
from Harlan Teklad (Madison, WI) and housed individually in a
temperature-controlled room (23 °C) with a 12-h light/dark cycle.
Hamsters were randomly assigned to four treatments (n ) 10/treatment)
with similar body weights/group. Hamsters had free access to food and
water during the 4-week experiment. Body weights were measured
weekly and food intakes measured daily. At the end of the feeding
period, diets were withdrawn from hamsters 16–18 h before they were
euthanized under CO2. Blood was collected by cardiac puncture and
centrifuged at 5000g for 15 min at 4 °C to prepare plasma that was
stored at -20 °C until analysis.
Plasma Lipid Analysis. Plasma total cholesterol and HDL choles-
terol concentration were measured with Sigma diagnostic kits (St. Louis,
MO). Plasma triglycerides were measured with Thermo Trace kits
(Louisville, CO). Non-HDL cholesterol was calculated by subtraction
of HDL cholesterol from total cholesterol and represented LDL + IDL
+ VLDL cholesterol.
Analysis of Urinary Excretion of Isoflavones. Hamsters were put
in metabolic cages for 24 h to collect urine during the last 2–3 days of
the feeding period. Duplicate urine samples/hamster (each sample
adjusted to 5 mL) were mixed with 5 mL of sodium acetate buffer
(0.2 M, pH 5.5), 50 µL of -glucuronidase/sulfatase (H2 type, Sigma-
Aldrich, St. Louis, MO), and 50 µL of 2,4,4-trihydroxydeoxybenzoin
(THB as an internal standard, 2 mg/mL) in a tube. After incubation
for 20 h at 37 °C on a shaker, 9 mL of sodium phosphate buffer (10
mM, pH 7.0) was added and the solution was passed through an Extrelut
QE column (EM Science, Gibbstown, NJ). The column was washed
twice with 18 mL of ethyl acetate (HPLC grade) and once with 10 mL
of ethyl acetate (HPLC grade). The effluent was collected in a round-
bottom flask and dried in a rotary evaporator (Buchler Instrument,
Fortlee, NJ), and the residues were dissolved in 9.8 mL of 20% ethanol
acidified by 200 µL of 1 N HCl. Five milliliters of the ethanol-dissolved
residue was slowly applied to a preconditioned Sep-Pak cartridge (C18,
Waters Corp., Milford, MA). The cartridge was washed twice with 2
mL of distilled water and eluent recovered in 2 mL of 80% methanol,
which was vortexed and filtered through a 0.45 µm PTFE filter (Alltech
Associates Inc., Deerfield, IL) prior to HPLC analysis.
The HPLC analysis was carried out on a Hewlett-Packard 1050
Series HPLC system. This system consisted of a photodiode array
detector (PDA), a quadruplicate pumping system, an autosampler, and
an HP Vectra 486/66 personal computer with Chem Station 3D software
(Hewlett-Packard Company, Scientific Instruments Division, Palo Alto,
CA). Daidzein, genistein, glycitein, and THB were detected and
quantified on an YMC-pack ODS-AM C18 reverse phase column (5
µm pore size, 25 cm × 4.6 mm, YMC, Inc., Wilmington, NC). Elution
was at a flow rate of 1 mL/min at room temperature with the following
solvents: 0.1% acetic acid in Milli-Q H2O (Millipore Co., Bedford,
MA) (solvent A) and methanol (solvent B). After injection of 20 µL
of sample, solvent B was increased from 30% to 50% over 45 min,
then held at 50% for 10 min, and decreased to 30% over 10 min.
Analytes were monitored from 190 to 350 nm. Ultraviolet absorbance
spectra were recorded, and area responses were integrated by Chem
Station 3D Software to identify isoflavones. Recovery based on the
THB internal standard was 84%, and recovery-adjusted urinary excre-
tion of each isoflavone as a percentage of dose ingested over 24 h was
reported.
Statistical Analysis. All statistical analyses were conducted with
the Statistical Analysis System (SAS, Release 8.2, SAS Institute Inc.,
Cary, NC). Values were expressed as means ( SD. The results were
analyzed by one-way analysis of variance (ANOVA). Differences
between treatments were determined by a least significant difference
test. An R of 0.05 was used to determine statistically significant
differences.
RESULTS AND DISCUSSION
This study determined whether daidzein, genistein, or gly-
citein lessened plasma cholesterol in female Golden Syrian
hamsters. Pure synthetic isoflavones were studied to avoid the
possible confounding effects of other alcohol extractable
components of soy protein such as soyasaponins. The diets were
well accepted. Hamsters ate a mean of 7.5 ( 1.5 g/day over 4
weeks. The initial mean body weight was 111.6 ( 0.1 g among
the groups. The final mean body weights were 127 ( 3 g, 126
( 4 g, 128 ( 4 g, and 127 ( 4 g for the groups fed casein,
daidzein, genistein, and glycitein diets, respectively. There were
no significant differences in daily food intake or initial or final
mean body weight among dietary treatment groups.
Hamsters fed purified synthetic glycitein had significantly
lesser plasma total and non-HDL cholesterol concentrations by
15% and 24%, respectively, compared with those fed casein (P
< 0.05). Daidzein or genistein did not differ in effects on plasma
cholesterol from either glycitein or the control diet (Table 1).
Few studies have reported the cholesterol-lowering effects
of pure isoflavones (8, 17, 18). Hamsters fed purified synthetic
daidzein at 1.3 mmol/kg diet (or ∼16 mg/(kg body weight/day))
for 10 weeks had significantly lesser plasma total and non-HDL
cholesterol concentrations by 22–24% and 30–38% compared
with those fed casein (8). In the present study, daidzein was
∼30% less than in the study of Song et al. (1.3 mmol of
daidzein/kg diet (8)), 0.9 mmol/kg diet (or ∼13 mg/(kg body
weight/day)) fed to the same numbers of animals. After a 4
week feeding period, daidzein lowered plasma total and non-
HDL cholesterol by 7% and 14%, respectively, compared with
casein (Table 1). Perhaps if a longer experiment was conducted,
a significant reduction of plasma total and non-HDL cholesterol
might be observed with 0.9 mmol of daidzein/kg diet. A mixture
of pure synthetic daidzein and genistein at 1.4 mmol/kg diet
(or ∼23 mg/(kg body weight/day); 2:1 ratio of genistein/
daidzein) fed for 21 days significantly lowered plasma triglyc-
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erides by 26% compared with the results with casein in
Sprague–Dawley rats (18). Plasma total cholesterol and trig-
lyceride concentrations were significantly lessened by 23–44%
and by 24–46%, respectively, in ovariectomized rats fed the
isolated pure isoflavone glucosides daidzin (25 or 50 mg/(kg
body weight/day)) or glycitin (50 mg/(kg body weight/day))
compared with casein (17). Both lean and obese SHP/N-cp rats
fed 20% casein plus 0.1% soybean isoflavones (3.9 mmol/kg
diet) for 20 weeks had significantly lesser plasma total (by
22–25%) and LDL cholesterol (by 26–31%) levels compared
with those of animals fed 20% casein (9). Therefore, soy
isoflavones had the ability to lessen plasma lipid concentrations,
separate from soy proteins in rodents. However, Fukui et al.
(24) reported that feeding 20% casein plus a 1.6% ethanol
extract containing 3.1 mmol of isoflavones/kg diet and 0.5%
dietary cholesterol for 2 weeks did not lessen plasma total
cholesterol compared with casein in male Sprague–Dawley rats.
The high level of cholesterol fed in this study (24) may have
overwhelmed the cholesterol-lowering efficacy of the ethanol-
extractable components, isoflavones and saponins. Compared
with male Golden Syrian hamsters fed 20% casein, feeding 20%
casein plus 0.02% soy isoflavone (0.8 mmol/kg diet; genistein/
daidzein/glycitein ) 1.4:1:0.2) and 0.08% dietary cholesterol
for 5 weeks did not significantly lower plasma total and VLDL
+ LDL cholesterol levels (25). This study was similar to the
present study in total isoflavone dose. In general, it seems that
isoflavone doses greater than ∼1.3 mmol/kg diet may be needed
to observe significant cholesterol lowering by isoflavones in
rodents fed diets that simulate a typical U.S. diet in total and
saturated fat and cholesterol content.
The mechanisms of soy isoflavones in lowering plasma
cholesterol levels are not clear. Soy isoflavones are estrogen-
like and bind estrogen receptors, especially ER-. Glycitein was
more estrogenic than genistein when given by gavage to
immature female mice over 4 days, causing uterine enlargement
(26). The loss of estrogen increased plasma concentrations of
total cholesterol, LDL cholesterol, and triglycerides and de-
creased HDL cholesterol in women (27, 28). Jensen (27)
investigated the changes of plasma lipid concentrations after
natural menopause in 170 premenopausal women. After meno-
pause, women had significantly increased plasma total choles-
terol (by 6%) and LDL cholesterol (by 8%) and decreased HDL
cholesterol (by 7%). Angelin et al. (29) obtained liver biopsies
from men treated with estrogen or nonestrogenic drugs for
prostatic carcinoma (control). Hepatic LDL receptor expression
was increased in estrogen-treated men compared with controls.
Although soy isoflavones may affect plasma lipid concentrations
through their estrogenic activity, the greater cholesterol-lowering
efficacy of glycitein than that of daidzein or genistein was due
mostly to bioavailability differences. The potential mechanisms
of isoflavones to reduce plasma lipid concentrations should be
further investigated.
The effects of soy isoflavones on plasma HDL cholesterol and
triglyceride concentrations are not consistent. Kawakami et al. (30)
reported that feeding 20% casein plus 0.37% isoflavone aglycone-
rich powder containing 3.8 mmol of isoflavones/kg diet and 0.3%
dietary cholesterol for 40 days significantly increased HDL
cholesterol and reduced triglycerides compared with casein in male
Sprague–Dawley rats. Compared with rats fed casein, the plasma
triglyceride concentration was significantly decreased (26%) in rats
fed a diet containing a mixture of pure synthetic daidzein and
genistein (18). However, the isoflavone-poor soy protein isolate
gave a significantly lower triglyceride level by 48% compared with
the case of male Sprague–Dawley rats fed casein (31). Ethanol-
extracted isolated soy protein significantly lowered triglycerides
and increased HDL cholesterol concentrations compared with
casein in female hamsters. Female hamsters fed daidzein had no
difference in plasma HDL cholesterol compared with those fed
casein (8). In our study, there were no significant differences in
plasma HDL cholesterol and triglyceride concentrations among
different dietary treatments (Table 1). These results were consistent
with those of other studies (1, 6, 9). Balmir et al. (1) reported that
plasma HDL cholesterol and triglyceride concentrations were not
significantly affected by dietary treatments (casein, casein with ∼0.3
mmol of total isoflavones/kg diet, casein with ∼0.6 mmol of total
isoflavones/kg diet, isolated soy protein (ISP), and ISP with alcohol
extract) in hamsters. Further studies are needed to investigate the
mechanism or effect of soy isoflavones on plasma HDL cholesterol
and triglycerides concentrations.
The percentage of urinary recovery of the ingested dose of
each isoflavone was greater in hamsters fed glycitein than in
those fed the other two isoflavones (Table 2). The percentage
of urinary recovery of the ingested dose of each isoflavone was
glycitein > daidzein > genistein in this study. Seemingly,
glycitein was absorbed to a greater extent than was daidzein or
genistein. A previous study (32) in our laboratory showed that
urinary isoflavone recovery was greater for glycitein than for
daidzein or genistein in hamsters fed Novasoy containing 1.18
or 1.77 mmol of total isoflavones/kg diet. Glycitein was more
bioavailable than daidzein and genistein, as reflected in the
urinary recovery of glycitein (52%) compared with those of
daidzein (17%) and genistein (18%). The average 24 h urinary
excretion of glycitein (∼43%) was significantly greater than that
Table 1. Plasma Cholesterol and Triglyceride Levels in Hamsters Fed Casein or Casein-Based Diets Containing Daidzein, Genistein, or Glyciteina,b
treatment
total cholesterol
(mmol/L)
HDL cholesterol
(mmol/L)
non-HDLc cholesterol
(mmol/L)
total cholesterol/HDL
cholesterol
triglyceride
(mmol/L)
casein 6.33 ( 0.32 a 3.75 ( 0.53 2.58 ( 0.31 a 1.69 ( 0.04 a 2.67 ( 0.61
daidzein 5.87 ( 0.79 ab 3.66 ( 0.58 2.22 ( 0.57 ab 1.60 ( 0.26 ab 2.22 ( 0.57
genistein 5.61 ( 0.87 ab 3.43 ( 0.64 2.19 ( 0.53 ab 1.63 ( 0.14 ab 2.40 ( 0.48
glycitein 5.34 ( 0.51 b 3.38 ( 0.86 1.95 ( 0.17 b 1.58 ( 0.03 b 2.29 ( 0.7
P value 0.018 0.249 0.025 0.048 0.109
a Values represent means ( SD, n ) 10. b Within a column, means followed by different letters are different (P < 0.05). c Represents the VLDL + IDL + LDL fractions
(by difference: total - HDL).
Table 2. Percentage of Urinary Isoflavone Recovery of Dose Ingested
over 24 h by Hamsters Fed Diets Containing Daidzein, Genistein, or
Glyciteina,b
daidzein (n ) 10) genistein (n ) 8) glycitein (n ) 7)
urinary recovery
(% ingested dose)
4.6 ( 1.8 b 2.2 ( 1.7 b 33.2 ( 25.7 a
a Values represent means ( SD. b Within a column, means followed by different
letters are different (P ) 0.0098).
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of daidzein or genistein (∼13%) in male Golden Syrian
hamsters, indicating that the bioavailability of glycitein was
greater than that of the other isoflavones (33). One hamster fed
glycitein produced daidzein in urine in our study. We excluded
this animal from the urinary isoflavone recovery data, but the
conversion of glycitein to daidzein has been documented
previously (34). Differing from hamsters, the urinary recoveries
in humans of daidzein, glycitein, and genistein were ∼52%,
∼47%, and ∼37%, respectively, in a study providing single
doses of soymilk or soygerm (glycitein-rich) to seven men and
seven women (all moderate in vitro fecal isoflavone degraders
in order to lessen interindividual variability in isoflavone uptake)
(35). This interspecies difference may be due to differences in
isoflavone metabolism and degradation by intestinal microbes.
Women who showed a lesser fecal anaerobic disappearance rate
of genistein and a faster gut transit time had greater genistein
bioavailability, as reflected in urinary recovery of genistein
compared with women who had a high genistein disappearance
rate and a long gut transit time (36). Three different in vitro
anaerobic fecal isoflavone disappearance phenotypes were
shown in humans and a negative correlation between plasma
isoflavone concentrations and fecal isoflavone disappearance rate
in eight young adult men (37). These findings indicated that
the variability in metabolic response to isoflavones may be due
to the relative ability of gut microbes to degrade isoflavones,
perhaps accounting for differences among species and isofla-
vones in apparent isoflavone absorption. The far greater apparent
absorption of glycitein than of daidzein or genistein in hamsters
suggests that this model is not ideal for understanding the human
health effects of glycitein or for understanding the bearing of
the structure/activity relationships among the three isoflavones
on cholesterol status. For comparing structure/activity relation-
ships between daidzein and genistein independent of bioavail-
ability, hamsters would be useful because these isoflavones have
similar apparent absorption in this animal model. This is not
the case for most humans, who show greater absorption of
daidzein than of genistein, but some individuals show similar
absorption of daidzein and genistein (38).
In conclusion, this study demonstrated that 0.9 mmol of
glycitein/kg diet lessened plasma cholesterol in female hamsters
compared with a casein control diet, an effect not observed with
purified daidzein or genistein at the same doses, and associated
with the far greater apparent absorption of glycitein than of the
other isoflavones.
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